Commentary

Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance

Peckham AM, Ananickal MJ, Sclar DA

Risk Management and Healthcare Policy 2018, 11:109-116

Published Date: 17 August 2018